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Abstract
Purpose—Considerations for using administrative claims data in research have not been well-
described. To increase awareness of how enrollment factors and insurance benefit use may 
contribute to observed estimates, we evaluated how differences in operational definitions of the 
cohort impacted estimates of disease prevalence.
Methods—We conducted a cross-sectional study estimating the prevalence of five 
gastrointestinal conditions using MarketScan claims data for 73.1 million enrollees. We extracted 
data obtained from 2009–2012 to identify cohorts meeting various enrollment, prescription drug 
benefit, or healthcare utilization characteristics. Next, we identified patients meeting the case 
definition for each of the diseases of interest. We compared the estimates obtained to evaluate the 
influence of enrollment period, drug benefit, and insurance usage.
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Results—As the criteria for inclusion in the cohort became increasingly restrictive the estimated 
prevalence increased, as much as 45% to 77% depending on the disease condition and the 
definition for inclusion in the cohort. Requiring use of the benefit and a longer period of 
enrollment had the greatest influence on the estimates observed.
Conclusions—Individuals meeting case definition were more likely to meet the more stringent 
definition for inclusion in the study cohort. This may be considered a form of selection bias, where 
overly restrictive cohort definitions may result in selection of a study population that may no 
longer represent the source population.
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Prevalence; Administrative claims data; Selection bias
INTRODUCTION
Administrative healthcare claims data offer the opportunity to study, at the population level, 
disease comorbidities, healthcare utilization patterns, and longitudinal studies of health 
outcomes. Frequently, claims data have been used in pharmacoepidemiologic studies. 
Because of the large number of patients included, administrative claims data have been 
increasingly used for studies of disease incidence and prevalence. For rare disease, claims 
data are one of the few resources available for assembling a sufficiently large enough cohort 
of cases for study. This type of epidemiologic research provides a basis for research or 
healthcare service resource allocation and informs public health efforts for disease 
prevention.
While numerous papers have been published on validation of disease-specific algorithms for 
case identification in administrative claims data, [1–8] and some methodological papers 
present case algorithms and strategies to maximize sensitivity or specificity, [9, 10] there has 
been little discussion of how enrollment factors for the health plan benefit could influence 
prevalence estimates. Estimating prevalence, or more specifically, a period prevalence, in 
administrative claims data necessitates defining an enrollment period from which the source 
population arises in addition to identification of cases within the source population. Given 
the variability in benefit plans, this may introduce bias when estimating disease prevalence. 
For example, not all enrollees have a prescription drug benefit, there are differences in 
lengths of enrollment periods, and there are different methods for defining enrollment 
periods. However, the impact of these differences has, to our knowledge, never been 
examined on prevalence estimates.
Our primary objective was to identify factors intrinsic to use of administrative claims data 
that may bias estimates of disease prevalence. Specifically, our aims were to 1) assess the 
influence of selection of enrollment period, using a minimum enrollment versus fixed 
enrollment period, on prevalence estimates, 2) assess the influence of selection of 
continuous (without interruption) versus total enrollment (sum of continuous periods of 
enrollment when there was >1 enrollment period), 3) assess the influence of restriction to 
plans with pharmacy benefit only versus without restriction, and 4) assess the influence of 
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restriction of the source population to patients who have evidence of having used their 
benefit plan.
MATERIALS AND METHODS
We conducted a cross-sectional study using the MarketScan administrative claims database 
(Truven Health Analytics – Ann Arbor, MI). This resource captures person-specific clinical 
utilization, expenditures, and enrollment information across inpatient, outpatient, and 
prescription drug services from a selection of large employers, health plans, and government 
and public organizations in the United States. The database includes commercial health data 
from approximately 100 payers. We restricted the data sample to individuals age 0–64 years, 
as individuals age 65 years and older may have dual enrollment in both a commercial and 
government-sponsored Medicare insurance plan.
We used International Classification of Diseases, ninth revision (ICD-9 CM) codes to 
characterize the disease status for several chronic gastrointestinal conditions, selected to 
represent a range of frequency of health care encounters and severities, namely Crohn’s 
disease, ulcerative colitis, Barrett’s Esophagus, eosinophilic esophagitis, and celiac disease. 
Case definitions were adapted from case algorithms previously applied in an administrative 
claims data setting (Supplementary Table A). There were no exclusions for insurance plan 
type; data were generated from claims arising through coverage from commercially 
provided insurance. No data were available on the specific insurance provider used.
We used data for individuals enrolled continuously for ≥ 6 months between January 1, 2009 
through December 31, 2012 to allow a minimum period of time for a diagnostic code(s) for 
a given condition to be documented, based on the anticipated pattern of care for the 
individual diseases. We examined the enrollment and demographic features of patients with 
the conditions above as compared to the source population and tested for statistically 
significant differences in the enrollment factors (Satterthwaite t-test for difference in mean 
days of enrollment; chi-square tests for difference in proportion of >1 enrollment period and 
proportion with a prescription drug benefit). The mean period of enrollment was calculated 
from the number of contiguous days the patient was enrolled from January 1, 2009 through 
December 31, 2012. For patients with gaps in enrollment, the mean duration of enrollment 
was based on the longest single period of continuous enrollment. Changes in health plan 
status are generally linkable in the MarketScan data. Therefore, enrollees who change health 
plans when changing employment are maintained as continuous beneficiaries when there is 
no interruption in coverage. Roughly 95% of enrollees had only a single period of 
enrollment during the period of study (Table B).
To evaluate the influence of enrollment factors on prevalence estimates, we calculated the 
prevalence of each condition after varying criteria for inclusion in the population (i.e. the 
denominator) from which the cases arose. These criteria included 1) duration of enrollment; 
2) enrollment continuity; 3) prescription benefit status; and 4) use of the health insurance 
benefit. For evaluating the influence of duration of enrollment we examined estimates based 
on inclusion of enrollees with ≥ 6 and 12 months of enrollment, and then, prevalence within 
finite enrollment periods of 12 or 24 months. We also examined estimates when restricting 
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the source population to those enrolled ≥ the mean number of days for cases from each of 
the disease definitions. All analyses were based on length of continuous enrollment, with the 
exception of the analyses described as total enrollment. Prevalence was calculated by 
dividing the number of individuals from the population meeting the case definition by the 
total number of individuals within the population, as defined by these enrollment factors and 
definitions. Data were restricted to claims made within the period of January 1, 2009 
through December 31, 2012. Where a finite enrollment period was specified, prevalence was 
based on diagnoses within this defined period. All prevalence estimates represent a period 
prevalence for the enrollment period specified.
The specific parameters for the analysis included: 1) enrollee enrollment dates (start and end 
date) for characterization of enrollment period and for characterizing the mean enrollment 
period for cases versus the source population; 2) continuous versus total enrollment, for 
characterizing differences in prevalence estimates when restricting the source population to 
those with or without continuous enrollment for the defined period of interest (for example, 
a patient could be characterized as having ≥ 12 months of continuous enrollment or ≥ 12 
months of total enrollment within a given period of time); and 3) whether the enrollee had a 
pharmacy benefit, for assessing the influence of restricting the source population to patients 
with a pharmacy drug benefit. In a secondary analysis, we evaluated whether estimates 
observed were influenced by restriction to health plan enrollees who had evidence of having 
used their benefit. We characterized the enrollee as a user of their health plan benefit if there 
was documentation of ≥ 1 instance of an ICD-9 CM code, Common Procedural 
Terminology (CPT) code, National Drug Code (NDC), or Healthcare Common Procedure 
Coding System (HCPCS) code during the enrollment period specified for each of the 
prevalence definitions. In instances where there was >1 period of continuous enrollment that 
met the criteria for inclusion, evidence of meeting the case definition could occur in any 
period that met criteria for inclusion. Finally, based on our observation that the enrollment 
characteristics of enrollees meeting case definition were different than those not meeting 
case definition, we restricted the cohort to patients with a minimum duration of continuous 
enrollment as defined by the mean duration of enrollment for a particular disease condition 
and, separately, enrollees with a minimum duration of enrollment as defined by the mean 
duration of enrollment for the source population. As this study used de-identified data, it is 
not considered human subjects research and was exempt from IRB review.
RESULTS
There were 73,129,577 enrollees that met study inclusion criteria of continuous enrollment 
for at least 6 months during the period of January 1, 2009 through December 31, 2012 -- 
93.2% of these patients contributed only a single period of continuous enrollment during the 
study period.
A comparison of the enrollment and demographic features of cases versus the underlying 
source population identified differences in length of enrollment and the proportion with a 
drug benefit (Supplementary Table B). Individuals meeting the case definition, across all 
disease conditions, were enrolled longer than the source population from which they arose. 
For example, the mean enrollment for the source population was 688 days, but mean 
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enrollment for cases ranged from 814 to 901 days. There were also differences between 
cases and the source population in the proportion with >1 continuous enrollment period, 
with cases less likely to have gaps in enrollment (Supplementary Table B). Similarly, 
individuals meeting case definition were more likely to have a prescription drug benefit in 
their insurance plan (Supplementary Table B).
Variation in prevalence estimates based on enrollment periods
In general, longer enrollment periods were associated with higher prevalence relative to 
shorter enrollment periods, and using the mean enrollment period of cases as the minimum 
requirement yielded the highest prevalence estimate (Table 1). For example, for Crohn’s 
disease, the prevalence estimate for ≥ 6 months of enrollment was 153.1 cases/100,000 and 
the estimate obtained when restricting to the longer enrollment period increased to 212.1 
cases/100,000 (27% increase). As described above, most enrollees did not have gaps in their 
enrollment and the prevalence estimates obtained from using minimum total enrollment, as 
compared to minimum continuous enrollment, were qualitatively the same (Supplementary 
Table C).
Source populations using finite enrollment periods (i.e. 12 or 24 months of calendar time), 
where the source population and cases contributed the same length of enrollment, generated 
differences in prevalence estimates with prevalence higher in populations followed for 
longer periods (Table 2). For example, prevalence for celiac disease in the 12 months for 
2010 and 2011 was 32.6/100,000 and 37.7/100,000, respectively, while the 24 month 
prevalence from 2010–2011 was 66.6/100,000 (43% increase). Similarly, prevalence for 
Barrett’s esophagus in the 12 months for 2010 and 2011 was 68.3 and 76.7/100,00, 
respectively, while the 24-month prevalence was 147/100,000 (49% increase). Prevalence 
estimates also increased with more recent enrollment periods, across all disease conditions 
(Table 2).
Variation in prevalence estimates based on drug benefits or benefit utilization
Requiring evidence of a prescription drug benefit for study inclusion shifted the prevalence 
estimates slightly higher, for both the minimum enrollment (Table 3) and finite enrollment 
period (Table 4) approaches. For example, for Crohn’s disease, inclusion of those enrolled 
during the finite 12-month period (2011) resulted in an increase in prevalence of Crohn’s 
disease from 119.4 to 121.2 for those with a drug benefit (Tables 2 and 4). Without the 
additional criteria of requiring a drug benefit, the prevalence among those enrolled ≥ 6 
months was 153.1 cases/100,000 (Table 3). Restricting the source population to those who 
were users of the health care system shifted estimates higher. For example, among those 
enrolled 24 months, the prevalence of Crohn’s disease increased from 172.4 to 186.2 with 
restriction of the source population to those individuals with evidence of using their 
insurance benefit (7% increase) (Tables 2 and 4).
Prevalence estimates obtained using the least restrictive criteria (≥ 6 months of total 
enrollment) were markedly different as compared to the estimates obtained using the most 
restrictive criteria we applied (minimum enrollment period as defined by the mean 
enrollment period of the cases, for those who were users of their benefit). For Crohn’s 
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disease this represented a 45% increase (153.1 cases/100,000 versus 221.8 cases/100,000), 
for ulcerative colitis a 65% increase (138.2 cases/100,000 versus 228.1 cases/100,000), for 
eosinophilic esophagitis a 70% increase (59.5 cases/100,000 versus 101.4 cases/100,000), 
for Barrett’s esophagus a 77% increase (133.6 cases/100,000 versus 237.0 cases/100,000), 
and for celiac disease a 69% increase (58.5 cases/100,000 versus 98.8 cases/100,000) in 
prevalence.
DISCUSSION
There are many examples of publications in the scientific literature reporting prevalence 
estimates obtained from administrative claims data using a variety of approaches. These 
include requiring a minimum enrollment period for the study population[1–4] restricting the 
study population to a finite period of time where everyone in the study population has the 
same opportunity to become a case,[5–8] and restricting the study population to those 
individuals who have at least one claim in the period of interest and/or have indication of 
having a prescription drug benefit as part of their health plan.[11] However, there is no 
consensus in the literature about the optimal way to approach this, or consideration of biases 
introduced by using a specific methodology. In the present analysis, we illustrate how these 
different approaches may yield substantially different estimates.
Estimating period prevalence when using administrative claims data necessitates not only 
employing an appropriate, ideally validated, algorithm to identify cases of interest (which is 
where much of the literature is focused), but also careful consideration of possible 
differences in enrollment characteristics for those with and without evidence of meeting the 
case definition. In the present analysis, individuals meeting case definitions had longer plan 
enrollment, greater continuity of enrollment, and were more likely to have a prescription 
drug benefit than individuals in the source population. By definition, cases are also more 
likely to have used their benefit plan. This observations are not unexpected, and may suggest 
that patients with chronic health conditions preferentially select and remain enrolled in plans 
with more comprehensive coverage. However, we also considered that the enrollment 
characteristics of cases may not be attributable to the disease -- rather patients with those 
enrollment characteristics may be more likely to be diagnosed. If this were to be true, then 
estimating prevalence from a less restrictive population (those enrolled for less time, or 
without a drug benefit) would result in a biased estimate as the cohort would not be 
representative of the source population giving rise to the cases. The demographic features of 
the individuals meeting the case definitions may contribute to the observed differences in 
enrollment characteristics, however the disease conditions represented individuals at varying 
age and sex distributions (Supplementary Table B). In other words, the pattern of longer 
enrollment periods, fewer disruptions in enrollment, and increase in proportion with a drug 
benefit, observed for cases as compared to the source population, was consistent across 
disease conditions that represented similar mean ages than the source population, and higher 
or lower proportion of males than the source population.
There are several important implications of these findings. First, applying increasingly 
stringent definitions for inclusion in the study population resulted in increasing prevalence 
estimates. The difference in prevalence estimates obtained across definitions was significant, 
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with increases in prevalence estimates from 45% to 77% based purely on how the study 
population was defined. This was because individuals meeting case definition were more 
likely to meet the more stringent definition for inclusion. This may be considered a form of 
selection bias, where overly restrictive inclusion criteria may lead towards selection of a 
study population that may no longer represent the source population.
However, utilizing more liberal inclusion criteria may not necessarily be the best practice 
either. Shorter enrollment requirements or not restricting to individuals with a pharmacy 
benefit may result in under-ascertainment of true cases, as sufficient observation time is 
required for patients to incur the necessary number and type of claims to meet administrative 
case definitions. This is particularly true for case definitions that require multiple claims, 
and for conditions in which episodes of care may be less frequent (i.e. it will take longer 
amounts of time to accumulate the necessary claims). We did not examine the influence of 
how the number of claims required for case definition could influence the estimates 
observed. Our case definitions were based on definitions that had been previously applied in 
the literature for these conditions. The association between increased restrictive inclusionary 
criteria and higher prevalence estimates was consistent across disease conditions, 
irrespective of the number of claims required for a given case definition.
Likely, selecting the appropriate enrollment period should depend on the disease being 
studied. Disease-specific factors would influence this, including disease severity, patterns of 
care (i.e. frequency of health encounters for well and poorly controlled illness), whether the 
disease is episodic, chronic or limited to a single acute episode, and the relative rarity of the 
disease. For conditions where patients receive frequent, regular healthcare (and claims), less 
restrictive enrollment requirements may be appropriate as this will ensure that the study 
population best represents the source population. However, for patients with less frequent or 
more episodic care, more restrictive enrollment criteria are needed in order to minimize 
under-ascertainment of cases. Therefore, a detailed understanding of the expected patterns of 
care for the disease under study as well as clinical judgment will be critical in establishing 
appropriate inclusion criteria. For conditions requiring infrequent healthcare, it is likely that 
administrative data may not be able to accurately identify disease prevalence. In our study, 
we examined only chronic health conditions. The influence of enrollment characteristics on 
estimates may differ for acute conditions. It may be that patients with acute illness are more 
similar to the source population as potentially the disease status may not have influenced 
their health coverage or length of enrollment. Conversely, patients with more comprehensive 
coverage may be more likely to seek care for an acute condition. These questions should be 
examined in future research.
This is not simply an academic issue, as there are potential real-world implications of these 
data. For example, these differences could influence rare disease status, defined as less than 
200,000 prevalent cases in the United States, which could impact orphan drug status and 
pharmaceutical development.[12] A lack of standardization in approach, across studies, 
could result in misleading assessments of changing disease prevalence across time, which 
could overemphasize or underemphasize the importance of a disease. This, in turn, could 
also lead to misinterpretation of the burden of disease, resulting in ill-informed resource 
utilization for disease research, prevention, and treatment.
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Administrative claims data are also frequently used in epidemiologic studies of exposure-
disease and disease-outcome. The differences we observed in enrollment characteristics of 
cases and non-cases may be relevant to these studies, particularly when these enrollment 
factors may also contribute to exposure or outcomes status, in which case enrollment factors 
could be an important source of confounding bias.
A limitation to this study was our inability to differentiate between enrollees who represent 
healthier individuals and those who have multiple sources of coverage. Estimates obtained 
when restricting the study population to users of their benefit increased prevalence estimates 
substantially. Although requiring some use of benefit may filter out those enrollees with 
more than one health plan, this approach may also exclude healthier patients and inflate 
prevalence estimates. We also do not know the quality of the coverage provided. This could 
have an influence on an enrollee’s likelihood to seek a diagnosis and/or follow-up treatment 
and thus contribute to their likelihood for being identified as a case.
Additionally, we are not able to know the “true” prevalence of the selected diseases to 
definitively conclude which approach is ideal. There is a potential that some patients may 
have been misclassified as having a disease condition as ICD-9 codes are imperfect in their 
measure of true disease status. However, knowing the actual prevalence was of secondary 
importance for the aims of this study, which involved demonstrating changes in the 
prevalence based on definition of the study population.
There are also a number of strengths to this study. First, we utilized a large administrative 
claims database that is widely used by academia and industry for research purposes. This 
allowed us to identify large numbers of cases for a range of conditions with different 
patterns of care, disease severity, and calculated prevalence to evaluate how enrollment 
factors could influence estimates in these different settings. Irrespective of disease type, the 
pattern of increasing prevalence with increasing restrictiveness of the inclusion criteria 
persisted across disease conditions. Second, we used a number of different study population 
definitions, but which also allow consideration for different patterns of care. Finally, we not 
only assessed enrollment periods, but also pharmacy benefits and use of benefits. Our results 
were consistent across a number of diseases, however we limited our study to chronic 
conditions of the gastrointestinal system. Our observations may not be generalizable to other 
disease conditions or conditions that are acute.
CONCLUSION
In conclusion, we demonstrate that the definition of the study population markedly impacts 
disease prevalence estimates in administrative claims data. This effect has not yet been 
reported in the literature, and likely impacts many published prevalence estimates. While 
our study design does not necessarily allow us to determine the “best” approach to defining 
the study population, we advise that researchers consider these issues when assembling a 
cohort for estimating prevalence, define the population for inclusion in a way in which 
reflects the appropriate patterns of care, explicitly report the rationale for their choices, and 
consider performing sensitivity analyses with different enrollment period definitions to 
examine the impact on the prevalence estimate. Overall, the minimum enrollment period 
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approach, with fewer restrictions in defining the study population, may lead to an 
underestimate of prevalence, particularly for conditions that require infrequent health care 
contacts. However, more restrictive approaches, using a finite enrollment period, requiring 
use of the benefit and/or a prescription benefit, may lead to an overestimate of prevalence, or 
a prevalence estimate representative of individuals with longer enrollment periods and a 
higher levels of benefit use and/or coverage. Although administrative claims data offer a 
rich opportunity for epidemiologic study of diseases, including descriptive studies of disease 
prevalence, recognition and documentation of the limitations and considerations for 
identifying an appropriate study population, a population reflective of the source population 
giving rise to the cases, is essential for using these data.
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Refer to Web version on PubMed Central for supplementary material.
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